Tucidinostat (Chidamide): Selectivity & Specificity

Tucidinostat (Chidamide) is a potent inhibitor of HDAC1 (95 nM), HDAC2 (160 nM), HDAC3 (67 nM), HDAC10 (75 nM), HDACs, AKT/mTOR pathway, MAPK pathway, HBV, osteoclast differentiation, osteoclast resorption, H3K27ac, JAK2, STAT3, leukemia cells, pancreatic cancer cells, NSCLC cells, adenoid cystic carcinoma cells, MDR breast cancer cells, Hodgkin lymphoma cells, ORC1, AURKA, proteasome, bortezomib resistance, BCL-2, BCL-xL, exemestane resistance, icotinib resistance (EGFR-TKI), crizotinib resistance (ALK inhibitor), EGFR-TKI resistance, JAK, PI3Kδ, CRBN, CDK4, CDK6, ESR1, PD-1, CD20, PD-L1, Treg, MDSC, MCL-1, CHK1, EBV, HDACs (Class I), HDACs (Class IIb), HIV-1 DNA, MLL, MLL-AF4, BIM, PARP, Notch1-MYC gene, CD8+ cells, CD22, p16 deletion. Tucidinostat (Chidamide) exhibits the greatest inhibitory potency toward HDAC3 (IC50 = 67 nM).